ClinicalTrials.gg
Temporarily not availableNCT07873281Updated Oct 14, 2026

Expanded Access Protocol for SPI-1005

An expanded access record providing Ebselen in Meniere's Disease, Meniere Disease and Meniere´s Disease, sponsored by Sound Pharmaceuticals, Incorporated. Temporarily not available. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Sound Pharmaceuticals, Incorporated · Expanded access

Updated Oct 14, 2026Newly registeredGo to Updates ↓
Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this protocol is to facilitate expanded access ("compassionate use") of SPI-1005 to Meniere's disease (MD) or sudden sensorineural hearing loss (SSNHL) patients who cannot gain access through ongoing clinical trial(s). Adult males and females, age 18 years or older, with Meniere's disease (MD) or sudden sensorineural hearing loss (SSNHL) who have exhausted available standard-of-care therapies and who may receive benefit from SPI-1005 treatment will be selected to participate in the Expanded Access Protocol, subject to Investigator and Sponsor discretion.

02

Conditions studied

  • Meniere's Disease
  • Meniere Disease
  • Meniere´s Disease
  • Meniere's Disease Aggravated
  • Sudden Sensorineural Hearing Loss
  • Sudden Sensorineural Hearing Loss (SSNHL)
03

In context

Meniere Disease

74 studies on the registry are indexed under Meniere Disease; 12 are open to participants now.

Browse Meniere Disease studies →

Lead sponsor

Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Meniere's Disease (MD) or Sudden Sensorineural Hearing Loss (SSNHL) who may benefit from SPI-1005 treatment.
  • Patients must have active symptoms including hearing loss within 90 days of study consent.
  • For SSNHL patients, the date of first onset of SSNHL must be between 30 days and 90 days of study consent.
  • All patients should have previously received the standard of care including treatment (systemic or intratympanic) prior to study consent.
  • Participation requires discretion and mutual agreement of patient, physician, and sponsor.
  • Patients must meet and agree to comply with the requirements.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe renal and hepatic insufficiency must be excluded.
  • Children (\<18 years of age) and females who are pregnant or breastfeeding are not eligible.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • SPI-1005 is a capsule that contains the investigational drug called ebselen. Ebselen is a new synthetic compound that has been found to reduce inflammation, remove potentially damaging oxidizing agents in the body, and provide protection to inner ear cells against harmful agents. Ebselen mimics the actions of glutathione peroxidase, a naturally occurring enzyme found in the body and the inner ear. Neither ebselen nor SPI-1005 have been approved by the FDA to treat any human disease or condition.

    Also known as: SPI-1005, SPI-1005 400mg

06

Where to request access

No study locations are listed for this record.

07

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT07873281
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
Oct 14, 2026
Last update
Oct 14, 2026
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion